Most companies think recalls are primarily about product retrieval.
FDA thinks they are about risk visibility.
And those are not the same thing.
Once a device enters the field, the regulatory conversation expands beyond how many units are affected, whether the issue appears contained, or whether the company believes it knows where the product is.
Because the FDA is also evaluating downstream exposure, uncontrolled distribution pathways, likelihood of public encounter, adequacy of communication, and whether the recall strategy matches the actual risk profile of the device.
That distinction matters more than many leadership teams realize.
Under 21 CFR 806, even voluntary recalls and field corrections trigger reporting obligations, effectiveness checks, and potentially public notification requirements depending on the level of risk and FDA’s assessment of exposure.
One of the more uncomfortable realities of recall management is that companies often assess the situation operationally:
We know where the devices went.
FDA tends to assess it probabilistically:
Where else could they realistically be?
That difference becomes especially significant for devices used in emergency care environments, distributed through multiple channels, or difficult to fully account for once deployed.
This clip walks through how FDA evaluates recall depth, effectiveness checks, public warning expectations, and field corrections—and why seemingly “contained” recalls can quickly become public-facing regulatory events once uncertainty enters the equation.
